---
document_datetime: 2024-10-17 11:15:32
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/gefitinib-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: gefitinib-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5414945
conversion_datetime: 2025-12-28 12:52:32.136836
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                             | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                       |
|----------------------|---------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0008               | Renewal of the marketing authorisation. Medicinal | 26/04/2023                                  | 23/06/2023                                  | SmPC and PL                      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Gefitinib Mylan in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

Gefitinib Mylan Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IAIN/0007   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                   | 15/06/2022   | 23/06/2023    | Annex II and PL                         |                   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-----------------------------------------|-------------------|
| N/0006      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                             | 25/04/2022   | 23/06/2023    | PL authorised                           |                   |
| T/0005      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                          | 24/09/2021   | 19/10/2021    | SmPC, Labelling and PL                  |                   |
| IB/0004/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH A.6 - Administrative change - Change in ATC product                          | 09/09/2021   | 19/10/2021 no | SmPC, Annex II, Labelling and PL longer | Code/ATC Vet Code |
| IA/0003/G   | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer Medicinal | 09/07/2020   | n/a           |                                         |                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->